Difference between revisions of "Levine RL, et al. Cancer Cell (2005) cited as Ref 316 in DOI: 10.1038/s41392-020-0110-5 (Q9579)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Volume (P103): 7, #quickstatements; #temporary_batch_1590009084631)
(‎Created claim: Page(s) (P105): 387-397, #quickstatements; #temporary_batch_1590074839150)
 
(One intermediate revision by the same user not shown)
Property / title
 +
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis (English)
Property / title: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis (English) / rank
 +
Normal rank
Property / Page(s)
 +
387-397
Property / Page(s): 387-397 / rank
 +
Normal rank

Latest revision as of 15:37, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Levine RL, et al. Cancer Cell (2005) cited as Ref 316 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Levine RL
    0 references
    0 references
    2005
    0 references
    Cancer Cell
    0 references
    7
    0 references
    Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis (English)
    0 references
    387-397
    0 references